Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 11/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.46 |
| ▸ | CFB | P00751 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolonidine SCHEMBL310600 | 0.90 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| Tolonidine SCHEMBL29391908 | 0.90 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL31442157 | 0.79 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL29458121 | 0.76 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL11759345 | 0.76 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| Nitric Acid SCHEMBL29355529 | 0.76 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| Nitric Acid SCHEMBL29393486 | 0.75 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL24658874 | 0.71 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL5827504 | 0.71 | HTR1D (0.66) | ADRA2AADRA2BADRA2CHTR1DHTR1B | |
| SCHEMBL29349477 | 0.71 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ADRA2A 331/4885ADRA2B 201/4885ADRA2C 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.